Daniel Siegwart

Daniel Siegwart has a long and varied work experience, beginning with a Research Intern role at Eli Lilly and Company in 2002. Daniel then moved to The University of Tokyo in 2006, where they were an EAPSI Fellow. In 2008, they became a Postdoctoral Fellow at MIT. After that, they joined UT Southwestern Medical Center in 2012, first as an Assistant Professor and then as an Associate Professor. In 2015, they co-founded ReCode Therapeutics.

Daniel Siegwart obtained a B.S. in Biochemistry from Lehigh University from 1999 to 2003, and a Ph.D. in Chemistry from Carnegie Mellon University from 2003 to 2008.